441 related articles for article (PubMed ID: 15643240)
1. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
4. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
[TBL] [Abstract][Full Text] [Related]
7. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
9. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
10. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
Kaufman JM; Graydon RJ
J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
[TBL] [Abstract][Full Text] [Related]
11. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
12. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A; Black AM; Emerson LE
BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
[TBL] [Abstract][Full Text] [Related]
13. The role of testosterone replacement therapy following radical prostatectomy.
Khera M; Lipshultz LI
Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
[TBL] [Abstract][Full Text] [Related]
14. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
Kaufman J
Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
[TBL] [Abstract][Full Text] [Related]
15. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
Miner M; Canty DJ; Shabsigh R
Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
[TBL] [Abstract][Full Text] [Related]
17. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
[TBL] [Abstract][Full Text] [Related]
19. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome.
McLaren D; Siemens DR; Izard J; Black A; Morales A
BJU Int; 2008 Nov; 102(9):1142-6. PubMed ID: 18540933
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]